Clinical Benefits of Ibuprofen Arginine: A Narrative Review.

IF 4.1 2区医学 Q1 CLINICAL NEUROLOGY

Pain and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-23 DOI:10.1007/s40122-025-00735-5

Piercarlo Sarzi-Puttini, Serge Perrot, Juan Perez-Cajaraville, Diego Maria Michele Fornasari, Franco Radaelli, Giustino Varrassi

引用次数: 0

Abstract

Ibuprofen arginine (IBA) combines well-established analgesic and anti-inflammatory properties with enhanced pharmacokinetics. The addition of arginine significantly improves solubility and absorption, leading to a faster onset of action compared to conventional ibuprofen. Clinical studies consistently demonstrate that IBA achieves meaningful pain relief within a shorter timeframe while maintaining a favorable safety profile. IBA's rapid action is particularly valuable in managing acute exacerbations of chronic pain and preventing central sensitization, thus improving patient comfort, adherence, and overall quality of life. By addressing both the inflammatory and nociceptive components of pain, IBA offers an effective and well-tolerated alternative in multimodal pain management strategies. This review explores the clinical benefits of IBA in pain management among various clinical settings.

查看原文本刊更多论文

布洛芬精氨酸的临床益处：综述。

布洛芬精氨酸（IBA）结合了良好的镇痛和抗炎特性，增强了药代动力学。精氨酸的加入显著改善了溶解度和吸收，与传统的布洛芬相比，导致更快的起效。临床研究一致表明，IBA在较短的时间内实现了有意义的疼痛缓解，同时保持了良好的安全性。IBA的快速行动在管理慢性疼痛急性加重和预防中枢致敏方面特别有价值，从而提高患者的舒适度、依从性和整体生活质量。通过解决疼痛的炎症和伤害成分，IBA在多模式疼痛管理策略中提供了一种有效且耐受性良好的替代方案。这篇综述探讨了在不同的临床环境中IBA在疼痛管理中的临床益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pain and Therapy CLINICAL NEUROLOGY-

CiteScore

6.60

自引率

5.00%

发文量

110

审稿时长

6 weeks

期刊介绍： Pain and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of pain therapies and pain-related devices. Studies relating to diagnosis, pharmacoeconomics, public health, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, acute pain, cancer pain, chronic pain, headache and migraine, neuropathic pain, opioids, palliative care and pain ethics, peri- and post-operative pain as well as rheumatic pain and fibromyalgia. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports, trial protocols, short communications such as commentaries and editorials, and letters. The journal is read by a global audience and receives submissions from around the world. Pain and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.